Chemistry and manufacturing services - task C10 chemical synthesis and process optimization of STF-1759
Ended Awarded Last action
- Contract number
- 75N93020F00002
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $411,405
Award facts
- Contract value 100% obligated
- $411,404.73 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$151,315 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | -$562,720 | |
| Funding Only Action | $562,720 | |
| Original award | $562,720 |
About this award
This federal contract award to Curia Global Inc., doing business as AMRI, is for chemistry and manufacturing services related to the chemical synthesis and process optimization of the compound STF-1759. The award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The contract has a ceiling value of $411,404.73 and a period of performance through September 30, 2021. It is a cost-plus-fixed-fee delivery order contract that is not designated as a small business set-aside. The contract is part of a larger Nonclinical Services for Development of Interventional Agents vehicle, indicating it is supporting broader drug discovery and development initiatives within NIAID's portfolio. Curia Global Inc. is a leading global contract development and manufacturing organization (CDMO) with expertise in pharmaceutical research and development services for federal agencies.
Quick answers
Who was awarded contract 75N93020F00002?
75N93020F00002 was awarded to Curia Global Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 31, 2020.
How much is contract 75N93020F00002 worth?
The government has obligated $411,405 on 75N93020F00002.
Is contract 75N93020F00002 an order under another contract?
Yes. 75N93020F00002 is a delivery order under 75N93018D00008, an indefinite delivery contract, on Nonclinical Services for Development of Interventional Agents.
Was contract 75N93020F00002 competed?
The extent of competition for 75N93020F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award